echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Qilu imatinib mesylate tablets will be approved soon

    Qilu imatinib mesylate tablets will be approved soon

    • Last Update: 2021-06-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Qilu Pharmaceutical entered the administrative examination and approval stage with imatinib mesylate tablets reported for production in category 4 imitations.


    Source: official website of the State Drug Administration

    Imatinib mesylate is a Bcr-Abl tyrosine kinase inhibitor developed by Novartis.


    According to data from Meinenet, in 2020, the total sales of imatinib mesylate tablets in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and Chinese urban entity pharmacies will be close to 25 100 million yuan.


    At present, 8 companies have submitted applications for imatinib mesylate tablets in the 4 categories.


    Since 2021, Qilu Pharmaceutical has been approved for marketing

    Source: Meinenet MED2.


    According to data from Minai.


    Source: Minei.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.